Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma

Shakthi Bhaskar, Brooj Abro, Tyler Fraum, Neha Mehta-Shah

Research output: Contribution to journalArticlepeer-review

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL and its role in treatment.

Original languageEnglish
Article numbere235578
JournalBMJ Case Reports
Volume13
Issue number8
DOIs
StatePublished - Aug 25 2020

Keywords

  • cancer intervention
  • therapeutic indications

Fingerprint Dive into the research topics of 'Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this